Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER vs AMINOSYN 10% (PH6)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CLINIMIX E 2.75/10 is a parenteral nutrition solution providing amino acids, dextrose, electrolytes, and calcium. Amino acids serve as substrates for protein synthesis, dextrose provides caloric energy, and electrolytes maintain fluid and electrolyte balance.
Aminosyn 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, helping to maintain nitrogen balance and support tissue repair and growth in patients unable to receive adequate nutrition enterally.
Parenteral nutrition for patients requiring caloric, protein, electrolyte, and fluid replacement when oral or enteral nutrition is not possible or insufficient.,Off-label: May be used in specific metabolic disorders or perioperative nutritional support.
Parenteral nutrition for prevention of nitrogen loss or treatment of negative nitrogen balance in patients where oral or enteral nutrition is impossible or insufficient
Intravenous infusion. Adult dose: 1-2 L per day, administered at a rate not exceeding 100 m L/hour initially, then adjusted based on metabolic and fluid requirements. Each liter contains amino acids 27.5 g, dextrose 100 g, and electrolytes including calcium.
Intravenous infusion: 1 to 1.5 g/kg/day (equivalent to 10 to 15 m L/kg/day of 10% solution) for adult patients with normal nutritional status; adjust based on metabolic needs.
Not applicable as a fixed combination product; individual components have half-lives: amino acids ~0.5-2 h, dextrose ~2-4 h, electrolytes vary (e.g., calcium ~2-4 h).
The terminal elimination half-life of individual amino acids varies (1–4 hours) depending on metabolic demand and renal function. For the amino acid mixture, the effective half-life is approximately 2 hours in patients with normal renal function. This short half-life necessitates continuous or frequent infusion to maintain stable plasma levels.
Amino acids are metabolized via transamination, deamination, and the urea cycle; dextrose is metabolized via glycolysis and the Krebs cycle; electrolytes are handled by renal and gastrointestinal mechanisms.
Amino acids are metabolized through deamination, transamination, and decarboxylation pathways, primarily in the liver, with nitrogen converted to urea via the urea cycle and carbon skeletons entering the Krebs cycle.
Renal excretion of infused amino acids and electrolytes; glucose is metabolized to CO2 and water; 100% of water and electrolytes excreted renally.
Amino acids from Aminosyn 10% are primarily utilized for protein synthesis and metabolic processes. Excess nitrogen is eliminated via the kidneys as urea (renal elimination accounts for >90% of nitrogen excretion). Minimal biliary/fecal elimination (<5%) occurs via unabsorbed amino acids in patients with malabsorption. In renal impairment, elimination is reduced.
Amino acids: minimal (<20% bound); calcium: ~45% bound to albumin; dextrose: negligible.
Amino acids exhibit low protein binding (<10%) to plasma proteins (primarily albumin). High-affinity binding is negligible; most amino acids circulate freely.
Amino acids: 0.5-1 L/kg (total body water); calcium: 0.6 L/kg; dextrose: 0.2-0.4 L/kg.
Volume of distribution (Vd) for amino acids in Aminosyn 10% ranges from 0.3–0.5 L/kg, approximating total body water. This reflects extensive distribution into extracellular and intracellular compartments.
100% intravenous bioavailability.
Bioavailability is 100% when administered intravenously. Not applicable for oral, intramuscular, or other routes; Aminosyn 10% is for IV use only.
For GFR < 30 m L/min: use with caution, reduce protein load to 0.6-0.8 g/kg/day; monitor phosphate and potassium levels closely. For GFR 30-60 m L/min: standard dosing but monitor electrolytes. For GFR >60 m L/min: no adjustment needed.
For GFR 30-59 m L/min: reduce dose to 0.8-1.0 g/kg/day. For GFR 15-29 m L/min: 0.6-0.8 g/kg/day. For GFR <15 m L/min or dialysis: 0.5-0.6 g/kg/day; monitor for azotemia.
For Child-Pugh class B or C: reduce amino acid content to 0.5-0.7 g/kg/day; avoid use in hepatic encephalopathy. For Child-Pugh A: standard dosing with monitoring of ammonia levels.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 30-50% and use a formulation with higher branched-chain amino acids. Child-Pugh Class C: avoid or use with extreme caution, adjust based on ammonia levels.
Weight-based dosing: initial infusion rate 0.1-0.15 m L/kg/hour, increase gradually to target 0.3-0.5 m L/kg/hour; maintain total fluid intake 100-150 m L/kg/day. Adjust based on glucose tolerance and electrolyte balance.
Infants (0-1 year): 2-3 g/kg/day (20-30 m L/kg/day). Children (1-12 years): 1.5-2.5 g/kg/day (15-25 m L/kg/day). Adolescents: 1-1.5 g/kg/day (10-15 m L/kg/day). Administer as continuous IV infusion.
Elderly patients: start at lower end of dosing range (e.g., 500 m L to 1 L per day) and titrate slowly; monitor for fluid overload, hyperglycemia, and electrolyte imbalances due to reduced renal and cardiac reserve.
Initiate at lower end of dosing range (0.8-1 g/kg/day) due to reduced renal function and increased risk of fluid overload; monitor serum electrolytes and renal function closely.
None.
None
Risk of infections due to central line use,Metabolic complications including hyperglycemia, acidosis, and electrolyte imbalances,Hepatic steatosis and cholestasis,Osteoporosis and bone demineralization,Withdrawal symptoms if discontinued abruptly
Risk of hyperammonemia, especially in patients with hepatic impairment,Risk of metabolic acidosis,Risk of fluid overload and electrolyte imbalances,Monitor for signs of infection or phlebitis at infusion site,Use with caution in patients with renal insufficiency as may worsen azotemia
Hypersensitivity to any component,Severe metabolic acidosis,Hyperglycemia uncontrolled by insulin,Severe electrolyte or fluid imbalances,Anuria or oliguria,Uncontrolled seizure disorders,Hepatic coma
Hypersensitivity to any component,Inborn errors of amino acid metabolism (e.g., maple syrup urine disease),Severe hepatic failure with encephalopathy,Severe azotemia or anuria
No direct food interactions as this is an intravenous solution. However, oral dietary intake should be coordinated with TPN to avoid overfeeding or electrolyte imbalances. Avoid concurrent administration of oral calcium or phosphate supplements without medical guidance due to potential precipitation risk in the IV line. Monitor total nutrient intake from all sources.
No specific food interactions. However, since this is used in parenteral nutrition, oral intake may be contraindicated. Adjustments may be needed if transitioning to oral feeding.
No known teratogenic risk; amino acids, dextrose, and electrolytes are essential nutrients. Inadequate nutrition may pose risks, but the formulation itself is not associated with teratogenicity. Standard precautions apply for intravenous therapy during pregnancy.
Amino acids are essential nutrients; no teratogenic risk is known when used at recommended doses. However, safety during pregnancy has not been established through controlled studies. First trimester: No evidence of fetal harm. Second/third trimester: Use only if clearly needed; monitor maternal and fetal status.
Considered compatible with breastfeeding. M/P ratio not determined; however, components are endogenous nutrients that are normally present in breast milk. Intravenous infusion results in maternal plasma levels similar to postprandial states, and no adverse effects on nursing infants are anticipated.
Excretion of amino acids into breast milk is not well studied. Considering the endogenous nature of amino acids, risk to infant is likely low if used at recommended doses. M/P ratio not determined.
Standard dosing based on nutritional requirements is generally appropriate. Monitor blood glucose closely due to increased insulin resistance in pregnancy. Adjust dextrose content if hyperglycemia develops. No specific pharmacokinetic changes necessitate dose adjustment beyond standard monitoring.
No specific dose adjustments required. Pregnancy may alter fluid and electrolyte needs; individualize dosing based on clinical status and laboratory parameters.
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER is a total parenteral nutrition (TPN) solution. Do not administer simultaneously with blood products through same IV line. Monitor for signs of phlebitis, infection, hyperglycemia, and electrolyte imbalances. Use inline filter (1.2 micron) to reduce particulate load. Check for precipitate formation; do not use if discolored or containing particulates. Assess daily labs including glucose, electrolytes, renal function, and liver enzymes. Adjust infusion rate gradually to avoid metabolic complications. For patients with renal or hepatic impairment, dose modifications may be necessary.
Aminosyn 10% (p H 6) is a crystalline amino acid solution used for parenteral nutrition. Monitor serum electrolytes, BUN, and ammonia levels due to risk of metabolic abnormalities. Adjust infusion rate to avoid hyperglycemia or hypoglycemia. Use with caution in renal or hepatic impairment. Check for compatible additives and avoid mixing with lipids in the same container unless validated.
This is a nutrition solution given intravenously (through a vein) to provide calories, protein, and electrolytes when you cannot eat by mouth.,Report any redness, swelling, pain, or warmth at the infusion site immediately.,You may experience changes in blood sugar; symptoms such as thirst, frequent urination, or headache should be reported.,Do not stop the infusion suddenly; the dose will be tapered as directed by your healthcare provider.,Inform your healthcare provider of all medications, including over-the-counter and herbal supplements, as some may interact with this product.,This solution is a clear liquid; do not use if it appears cloudy, discolored, or contains particles.,Follow any dietary restrictions advised by your healthcare team; this solution is used because oral intake is inadequate.
Report any signs of infection at the IV site, such as redness, swelling, or pain.,Inform your healthcare provider if you experience nausea, vomiting, or dizziness.,This solution provides essential nutrients; do not stop treatment without consulting your doctor.,Keep an eye on your blood sugar levels if you have diabetes.,Do not take any other nutritional supplements without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER vs AMINOSYN 10% (PH6), answered by our medical review team.
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by CLINIMIX E 2.75/10 is a parenteral nutrition solution providing amino acids, dextrose, electrolytes, and calcium. Amino acids serve as substrates for protein synthesis, dextrose provides caloric energy, and electrolytes maintain fluid and electrolyte balance.. AMINOSYN 10% (PH6) is a Parenteral Nutrition Solution that works by Aminosyn 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, helping to maintain nitrogen balance and support tissue repair and growth in patients unable to receive adequate nutrition enterally.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER and AMINOSYN 10% (PH6) depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous infusion. Adult dose: 1-2 L per day, administered at a rate not exceeding 100 m L/hour initially, then adjusted based on metabolic and fluid requirements. Each liter contains amino acids 27.5 g, dextrose 100 g, and electrolytes including calcium.. The standard adult dose of AMINOSYN 10% (PH6) is: Intravenous infusion: 1 to 1.5 g/kg/day (equivalent to 10 to 15 m L/kg/day of 10% solution) for adult patients with normal nutritional status; adjust based on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER and AMINOSYN 10% (PH6) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. No known teratogenic risk; amino acids, dextrose, and electrolytes are essential nutrients. Inadequate nutrition may pose risks, but the formulation itself is not associated with t. AMINOSYN 10% (PH6) is classified as Category C. Amino acids are essential nutrients; no teratogenic risk is known when used at recommended doses. However, safety during pregnancy has not been established through controlled studi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.